Newsroom | 4218 results

DENVER--(BUSINESS WIRE)--Cleerly, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) from March 29-31, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share its late-breaking findings on Artificial Intelligence-based Quantitative Computed Tomography’s (AI-QCT’s) role in identifying risks of future major adverse cardiovascular events (MACE) in women. Onsite, Cleerly...

WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the analytical validation of NavDx+Gyn, an important extension of the NavDx® blood test. NavDx+Gyn is a cell-free DNA-based fragmentomic profiling assay that enhances the detection and monitoring of human papillomavirus (HPV)-driven gynecologic cancers. Leveraging the robust foundation of the NavDx test, which has been validated in over 35 peer-reviewed publica...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the U.S. launch of Flyrcado™ (flurpiridaz F 18) injection at the 2025 American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place March 29-31 in Chicago. Additionally, the company will showcase new AI-powered innovations, reflecting its strategy to leverage AI to help increase efficiency and enable seamless integration of data across the cardiology care pathway. GE HealthCare has been investing in...

DUBLIN--(BUSINESS WIRE)--The "Radiopharmaceuticals in PET Imaging Market - A Global and Regional Analysis: Focus on Radioisotope Type, Application, End User, and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global radiopharmaceuticals market in PET imaging is driven by an increasing demand for early detection of diseases, particularly cancers, and neurological conditions. With continuous technological advancements, in...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, has announced a Technology Alliance Agreement with the Chan Zuckerberg Institute for Advanced Biological Imaging (CZ Imaging Institute). This agreement aims to develop new technologies to enable researchers to better visualize human cells, significantly advancing scientific research and discovery. Cryo-electron microscopy (cryo-EM) is an essential tool in disease research and creating lifesaving...

WASHINGTON--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, today commended members of the U.S. House and Senate for reintroducing the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act. The legislation is led by Representatives Joe Morelle (D-NY-25) and Brian Fitzpatrick (R-PA-01). The SCREENS for Cancer Act reauthorizes a critical program – the National Breast and Cervical Cancer Early Detection Program (NBCCEDP)...

MEDIA, Pa.--(BUSINESS WIRE)--Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions for radiology practices, today announces the addition of Radiology Alliance of Maine (RAM) to its roster of radiology revenue cycle and practice management clients. Radiology Alliance of Maine is a 9-doctor group providing diagnostic and interventional radiology services at the MaineGeneral Health hospitals in Augusta and Waterville, ME. Unde...

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare & Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav® Infusion System, effective April 1, 2025. This new code, C8004, provides reimb...

BASEL, Switzerland--(BUSINESS WIRE)--New Publication Reveals the Impact of Socioeconomic Factors on Health Outcomes and Importance of Self-Care...

SAN JOSE, Calif.--(BUSINESS WIRE)--Evident Vascular, Inc., a medical technology company developing a best-in-class intravascular ultrasound (IVUS) platform powered by artificial intelligence, today announced the successful closing of its Series B financing with new investors Shangbay Capital and two undisclosed multinational strategics joining founding investor Vensana Capital. The funding will accelerate the development of the Company’s advanced IVUS technology designed to enhance vascular ima...